NDA 211155 · Secura
Copiktra
Duvelisib · Oral
Accelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Oct 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Sep 24, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
58
5 Phase 3, 8 recruiting
FAERS reports
853
488 serious, 181 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: TREATMENT-RELATED MORTALITY AND SERIOUS TOXICITIES: INFECTIONS, DIARRHEA OR COLITIS, CUTANEOUS REACTIONS, AND PNEUMONITIS Treatment-related mortality occurred in 15% of COPIKTRA-treated patients [see Warnings and Precautions ( 5.1 )] . Fatal and/or serious infections occurred in 31% of COPIKTRA-treated patients. Monitor for signs and symptoms of infection. Withhold COPIKTRA if infection is suspected [see Warnings and Precautions ( 5.2 )]. Fatal and/or serious diarrhea or colitis occurred in 18% of COPIKTRA-treated patients. Monitor for the development of severe diarrhea or colitis. Withhold COPIKTRA [see Warnings and Precautions ( 5.3 )] . Fatal and/or serious cutaneous reactions occurred in 5% of COPIKTRA-treated patients. Withhold COPIKTRA [see Warnings and Precautions ( 5.4 )] . Fatal and/or serious pneumonitis occurred in 5% of COPIKTRA-treated patients. Monitor for...
What it is approved for
From the label in effect Dec 18, 2025.
COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines of systemic therapy. Limitations of Use: COPIKTRA is not indicated or recommended for the treatment of any patients with CLL or SLL as initial or second line treatment due to an increased risk of treatment-related mortality. COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines lines of systemic therapy. ( 1 ) Limitations of Use : COPIKTRA is not indicated or recommended for the treatment of any patients with CLL or SLL as initial or second line treatment due to an increased risk of treatment-related mortality. ( 1 )
Mechanism: Duvelisib is an inhibitor of PI3K with inhibitory activity predominantly against PI3K-δ and PI3K-γ isoforms expressed in normal and malignant B-cells. Duvelisib induced growth inhibition and reduced viability in cell lines derived from malignant B-cells and in primary CLL tumor cells. Duvelisib inhibits several key cell-signaling pathways, including B-cell receptor signaling and CXCR12-mediated chemotaxis of malignant B-cells. Additionally, duvelisib inhibits CXCL12-induced T cell migration and M-CSF and IL-4 driven M2 polarization of macrophages.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 24, 2018 Original approval · Efficacy · priority review OrphanLetterReviewREMS
- Sep 24, 2018 Original approval · Type 1 - New Molecular Entity · priority review Accelerated approvalOrphanLabelLetterReview
2 products under this application
- COPIKTRA · DUVELISIB 25MG · CAPSULE, ORAL · Prescription
- COPIKTRA · DUVELISIB 15MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Duvelisib" as an intervention, any sponsor and status, largest first.
- A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate AlonePivotal-lookingCompleted
SecuraBioIndustry
NCT01851707 · 322 participants · Start Apr 2013 · Primary completion Dec 2014
Drug: IPI-145; Placebo · For: Rheumatoid Arthritis
Sites: Pleven, Bulgaria; Plovdiv, Bulgaria; Rousse, Bulgaria · 64 sites in all
- A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)Pivotal-lookingCompleted
SecuraBioIndustry
NCT02004522 · 319 participants · Start Nov 2013 · Primary completion May 19, 2017
Drug: Duvelisib; Ofatumumab · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: La Jolla, California; Denver, Colorado; Altamonte Springs, Florida · 92 sites in all
- Genotype-guided Treatment in Newly Diagnosed PTCLPivotal-lookingRecruiting
Ruijin HospitalAcademic, hospital or other
NCT05675813 · 264 participants (planned) · Start Feb 13, 2023 · Primary completion Jul 15, 2026
Drug: CHOP+selinexor+5-Azacitidine; CHOP+duvelisib+5-Azacitidine and 2 more · For: Peripheral T Cell Lymphoma
Sites: Shanghai, China
SecuraBioIndustry
NCT01476657 · 210 participants · Start Oct 2011 · Primary completion Dec 2016
Drug: IPI-145 (duvelisib) · For: Hematologic Malignancies
Sites: New York, New York; Columbus, Ohio; Nashville, Tennessee · 4 sites in all
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaPivotal-lookingRecruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT04803201 · 170 participants (planned) · Start Oct 8, 2021 · Primary completion May 19, 2027
Drug: Cyclophosphamide; Doxorubicin and 5 more · For: Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Follicular T-Cell Lymphoma and 4 more
Sites: Little Rock, Arkansas; Duarte, California; La Jolla, California · 96 sites in all
- A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Pivotal-lookingCompleted
SecuraBioIndustry
NCT03372057 · 156 participants · Start Feb 22, 2018 · Primary completion Dec 22, 2023
Drug: Duvelisib; Duvelisib and 1 more · For: Peripheral T-cell Lymphoma
Sites: Duarte, California; Irvine, California; Los Angeles, California · 36 sites in all
- A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular LymphomaStatus unknown
Shanghai YingLi Pharmaceutical Co. Ltd.Industry
NCT04379167 · 140 participants (planned) · Start Dec 30, 2020 · Primary completion Dec 30, 2022
Drug: YY-20394 · For: Follicular Lymphoma
SecuraBioIndustry
NCT01882803 · 129 participants · Start Jun 17, 2013 · Primary completion Nov 18, 2020
Drug: Duvelisib · For: Indolent Non-Hodgkin Lymphoma
Sites: Los Angeles, California; Whittier, California; Denver, Colorado · 69 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product use in unapproved indication237
- diarrhoea112
- death111
- off label use106
- fatigue82
- prescribed underdose65
- product use issue58
- nausea50
- pneumonia42
- pyrexia41
- malignant neoplasm progression40
- rash38
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 17 |
| 2017 | 7 |
| 2018 | 20 |
| 2019 | 121 |
| 2020 | 158 |
| 2021 | 98 |
| 2022 | 88 |
| 2023 | 68 |
| 2024 | 65 |
| 2025 | 96 |
| 2026 | 113 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Copiktra (Duvelisib)
2024 spending
$31.4M
Beneficiaries
195
854 claims
Per beneficiary
$160,886
$468.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $6,678,552 |
| 2023 | $20,690,440 |
| 2024 | $31,372,840 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Horwitz SM, Nirmal AJ, Rahman J, et al. · Nat Med 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Frustaci AM, Tedeschi A, Deodato M, et al. · Future Oncol 2019 · Clinical Trial, Phase III, Multicenter Study
- Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z, Zhou H, Xu J, et al. · Front Immunol 2022 · Meta-Analysis, Systematic Review
- Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
Mehta-Shah N, Zinzani PL, Jacobsen ED, et al. · J Clin Oncol 2026 · Clinical Trial, Phase II, Multicenter Study
- Duvelisib in indolent non-Hodgkin lymphoma.
Das M · Lancet Oncol 2019 · Clinical Trial, Phase II
- Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).
Patel VM, Balakrishnan K, Douglas M, et al. · Leukemia 2017 · Clinical Trial, Phase I
Sponsor: Secura
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.